Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
Our top-notch dedicated system is used to design specialised libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology employs molecular simulations to explore a wide array of proteins, capturing their dynamic states both individually and within complexes. Through ensemble virtual screening, we address conformational mobility, uncovering binding sites within functional regions and remote allosteric locations. This thorough exploration ensures no potential mechanism of action is overlooked, aiming to discover novel therapeutic targets and lead compounds across an extensive spectrum of biological functions.
Our library stands out due to several important features:
partner
Reaxense
upacc
P30511
UPID:
HLAF_HUMAN
Alternative names:
CDA12; HLA F antigen; Leukocyte antigen F; MHC class I antigen F
Alternative UPACC:
P30511; Q5JQI8; Q5JQJ1; Q5SPT5; Q860R0; Q8MGQ1; Q8WLP5; Q95HC0; Q9TP68
Background:
HLA class I histocompatibility antigen, alpha chain F (HLA-F) is a non-classical major histocompatibility class Ib molecule. It plays a crucial role in immune surveillance, tolerance, and inflammation. HLA-F functions in two forms: as a heterotrimeric complex with B2M and a peptide, and as a peptide-free open conformer (OC). It presents non-canonical self-peptides with post-translational modifications and interacts with receptors like LILRB1, KIR3DS1, and KIR3DL2 to modulate immune responses.
Therapeutic significance:
Understanding the role of HLA class I histocompatibility antigen, alpha chain F could open doors to potential therapeutic strategies.